McKesson (MCK) 10-K Summary — Year Ended Mar 31, 2025
McKesson is a diversified healthcare services company operating through four segments. In the latest fiscal year, revenue grew, operating income and net income were reported, and cash from operations was positive.
Key takeaway
Year ended Mar 31, 2025 · FY2026 10-K
McKesson is a diversified healthcare services company operating through four segments. In the latest fiscal year, revenue grew, operating income and net income were reported, and cash from operations was positive.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$359.1B
Revenue reported for the fiscal year.
Operating income
$4.4B
Income from operations reported for the year.
Net income
$3.3B
Net income reported for the year.
Operating cash flow
$6.1B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2022 | $264B | n/a |
| Mar 31, 2023 | $276.7B | +4.8% |
| Mar 31, 2024 | $309B | +11.7% |
| Mar 31, 2025 | $359.1B | +16.2% |
Business overview
McKesson is a diversified healthcare services leader that partners with biopharma companies, care providers, pharmacies, and others to make quality care more accessible and affordable. The company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International.
Financial performance
Revenue for the period increased compared to prior years, with operating income and net income both reported. Operating cash flow was also positive, reflecting overall financial activity.
Material risks
The filing includes a risk factors section, but the supplied text does not contain specific descriptions of those risks. Therefore, no material risks can be identified from the provided context.
Liquidity and capital
The company reported a significant cash position and a high debt-to-capital ratio, with working capital negative. Cash equivalents are held in high-grade instruments to mitigate short-term investment risk.
What to watch
Monitor the company's debt-to-capital ratio and working capital trends in the next filing.